Biosciences Investment Portfolios

Stocks
Oppenheimer Affirms Outperform Rating for Ventyx Biosciences Nov 8, 2024
Pharmaceuticals
Ventyx Biosciences Faces Setback as Crohn's Disease Drug Candidate VTX958 Fails Phase 2 Trial Jul 29, 2024
Companies
Cellectar Biosciences Prepares Key Opinion Leader Event for CLOVER WaM Trial Analysis Jun 28, 2024
Earnings
Enveric Biosciences Reveals Decline in Revenue for Q3 2023 Amid Advancements of Psychedelics into Clinical Trials Nov 15, 2023